Drug Profile


Alternative Names: 23F2G; Hu23F2G; LeukArrest

Latest Information Update: 17 May 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ICOS Corporation
  • Class Anti-ischaemics; Monoclonal antibodies
  • Mechanism of Action Integrin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Cerebral vasospasm; CNS trauma; Multiple sclerosis; Myocardial infarction; Peripheral arterial occlusive disorders; Shock; Stroke; Vascular restenosis

Most Recent Events

  • 17 May 2002 Discontinued - Preclinical for Cerebral vasospasm in USA (unspecified route)
  • 17 May 2002 Discontinued - Preclinical for CNS trauma in USA (unspecified route)
  • 17 May 2002 Discontinued - Preclinical for Peripheral arterial occlusive disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top